

REMARKS

This is in response to the Official Action of June 11, 2008. The points raised therein are addressed below in the order originally set forth.

The requirement for restriction having been made final, non-elected claims 41-47 and are cancelled herein, without prejudice to the filing of a divisional application theon.


Claims 49-50, 53-56, 58-60, and 64-70 are also cancelled herein, for the purpose of simplifying the issues, without prejudice or disclaimer.

Claim 57 has been corrected in the manner suggested by the Examiner, and it is respectfully submitted that this rejection may now be withdrawn.

Claims 48-66 stand rejected under the first paragraph of 35 USC 112 as lacking enablement for scope beyond that identified as being enabled in the paragraph of the action bridging pages 2-3. (Please note that, regarding the issue of chimeric animals raised in the Official Action on page 4, applicants respectfully note that it is the chimeric animals that are the useful invention. These are not founder mice – they are the mice tested for overexpression of FSH- β and superovulation (and useful because of those traits)). Support for these amendments is found in original claim 44, as well as on page 6 of the specification, last 2 lines, page 7, first 10 lines (tet operator language). Support for the amendment adding ‘female’ and ‘mouse’ to modify ‘transgenic’ and ‘oocytes’ instead of ‘gametes’ is found in original claim 50 and on page 32 of the specification, Example 3. Accordingly, it is respectfully submitted that this rejection may now be withdrawn.

Applicants respectfully submit that all issues raised in the Official Action have been addressed, and that the claims are now in condition for allowance. Applicants respectfully request notice to that effect.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665

USPTO Customer No. 20792

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401

Doc. 693317